Gaining Insights into Clinical Testing of Engineered Phage Cocktail Targeting E. coli
Time: 2:00 pm
day: Day One
Details:
- Revealing clinical results from Phase I trial on orally dosed, CRISPR-armed phage designed for precision killing of E. coli
- Improving safety, tolerability, and microbiological efficacy endpoints for superior patient results
- Consolidating the next steps in development and success of CRISPR-led phage therapy
